EXCL-100, 600 MG Oral Tablet ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	1

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05428150 (ClinicalTrials.gov)	August 8, 2022	15/6/2022	Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers	Randomized, Crossover, Multi-Dose, Steady State, Comparative Pharmacokinetics and Relative Bioavailability Study of EXCL-100 Pirfenidone-Sustained Release Tablet (EXCL-100), and Esbriet® in Healthy Volunteers	Idiopathic Pulmonary Fibrosis	Drug: Esbriet 267 MG Oral Capsule;Drug: EXCL-100, 600 MG Oral Tablet	Excalibur Pharmaceuticals, Inc.	NULL	Completed	18 Years	65 Years	All	32	Phase 1	United States